MedTrace Logo

Combining Default Choices and a Decision Aid to Improve Tobacco Cessation

NCT04868474 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 287

Last updated 2024-05-16

No results posted yet for this study

Summary

The FIRST cluster randomized trial will evaluate the effect of 1) a training program encouraging general practitioners to offer smoking cessation treatment as a default choice to all current smokers consulting a general practitioner (GP), and 2) an interactive, electronic decision aid to guide smoking cessation treatment, on the proportion of current smokers seen in primary care who have quit smoking 6 months after a baseline visit to their GP, as compared to enhanced usual care.

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

Training program and decision aid

1\) a one-time, in-person, 2.5-hour training program encouraging participating GPs to present quitting smoking with a quit aid as the default choice to their eligible patients, and 2) access to an electronic decision aid that presents available quit aids. The 2.5-hour training program consists of: 1.5 hours of didactic teaching, with information about pharmacologic quit aids, electronic cigarettes, presenting quitting as a default choice, the decision aid, and a video of a model consultation. This is followed by 1 hour of role plays to practice presenting quitting as a default choice using the decision aid.

BEHAVIORAL

Refresher course

A 45-minute refresher training about smoking cessation that does not aim to change GP behaviour. It will include the same information about pharmacologic quit aids and electronic cigarettes.

Sponsors & Collaborators

  • Tobacco Control Fund Switzerland

    collaborator OTHER_GOV

  • Swiss Medical Association (FMH)

    collaborator OTHER_GOV

  • Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

    lead OTHER

Principal Investigators

  • Kevin J Selby, MD · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2023-11-30
Completion
2024-02-29

Countries

  • France
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04868474 on ClinicalTrials.gov